To read the full story, subscribe or sign in.

Biological Terrorism: Worth Fighting, But Not Investing

Oct. 1, 2001

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for May 11, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

BioWorld

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Concept art for "unlocking the secrets of the mind"

New assay for drug discovery against chemo-induced peripheral neuropathy

BioWorld Science

A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...